Kamal Eldin Ahmed, MD
Nephrology · Yuma, AZNPI 1952352411
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.3%), speaking fees and education — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by AstraZeneca at 54.6% of the total. Reporting peaked in 2020 at $3,065 and has fallen 58.5% since, to $1,273 in 2025.
Across 130 payments — averaging $45.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Ardelyx, Inc.$438
- Travere Therapeutics, Inc.$359
- GSK$222
- Akebia Therapeutics Inc$212
- Calliditas Therapeutics US Inc.$189
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$2,70046%
- Food & beverage$3,09352%
- Education$1172%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $3,229 |
| Ardelyx, Inc. | 8 | $438 |
| Travere Therapeutics, Inc. | 25 | $359 |
| GSK | 8 | $222 |
| Akebia Therapeutics Inc | 6 | $212 |
| Calliditas Therapeutics US Inc. | 4 | $189 |
| Fresenius USA Marketing, Inc. | 8 | $140 |
| Bayer | 8 | $131 |
| Otsuka America Pharmaceutical, Inc. | 6 | $131 |
| Novartis | 5 | $121 |
| Amgen | 6 | $112 |
| Outset Medical Inc | 1 | $101 |
| OPKO Pharmaceuticals, LLC | 5 | $97 |
| Vifor Pharma, Inc. | 5 | $80 |
| Mallinckrodt Hospital Products Inc. | 1 | $70 |
| Baxter Healthcare | 1 | $62 |
| Amicus Therapeutics, Inc. | 3 | $57 |
| AMAG Pharmaceuticals, Inc. | 3 | $50 |
| Kyowa Kirin, Inc. | 1 | $50 |
| Boehringer Ingelheim | 1 | $22 |
| Sanofi | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,910 in reported general payments places this provider in the 80th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Hcl | 36 | $67,187 |
| Sevelamer Carbonate | 199 | $63,558 |
| VelphoroSucroferric Oxyhydroxide | 23 | $59,184 |
| LokelmaSodium Zirconium Cyclosilicate | 70 | $51,770 |
| Calcium Acetate | 268 | $30,554 |
| FarxigaDapagliflozin Propanediol | 32 | $25,434 |
| VeltassaPatiromer Calcium Sorbitex | 24 | $13,960 |
| Cinacalcet Hcl | 40 | $12,020 |
| Calcitriol | 432 | $6,668 |
| Midodrine Hcl | 73 | $5,823 |
| Potassium Chloride | 97 | $2,241 |
| Losartan Potassium | 162 | $1,748 |
| Fluconazole | 19 | $1,507 |
| Nifedipine ErNifedipine | 56 | $1,381 |
| Amlodipine Besylate | 153 | $1,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLokelma, Farxiga | $3,229 | $77,204102 claims |
| Fresenius USA Marketing, Inc.Velphoro | $140 | $59,18423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 259 nephrology providers in Arizona.
Other nephrology in Yuma
- Claudia VelardeYuma$8K
- Randy CooperPeoria$597K
- Minesh RajpalPeoria$403K
- Umar WaheedPeoria$150K
- Amer KhanPeoria$71K
- Samer Bani HaniPhoenix$54K
- Aneesha ShettyTucson$34K
- Leslie ThomasPhoenix$22K
- Alexander NimriPhoenix$21K
- Saeed ShaffiScottsdale$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.